Pulmonary hypertension risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Pulmonary hypertension (PH) is a multifactorial disease involving genetic and environmental risk factors. Risk factors for pulmonary arterial hypertension include [[BMPR2]] [[mutation]], [[connective tissue disease]], [[HIV infection]], [[portal hypertension]], [[fenfluramine]] use, and [[congenital heart disease]] with [[shunt]]. | Pulmonary hypertension (PH) is a multifactorial disease involving genetic and environmental risk factors. Risk factors for pulmonary arterial hypertension include [[BMPR2]] [[mutation]], [[connective tissue disease]], [[HIV infection]], [[portal hypertension]], [[fenfluramine]] use, and [[congenital heart disease]] with [[shunt]]. [[Left heart]] and [[lung]] diseases are risk factors for PH. Patients with a [[hypercoagulable state]] (such as the presence of [[lupus anticoagulant]], deficiency of [[protein C]], [[protein S]], or [[antithrombin III]], [[inflammation#Chronic inflammation|chronic inflammatory disorders]], [[myeloproliferative syndrome]]s, and [[splenectomy]]) are at an increased risk for chronic [[thromboembolic]] pulmonary hypertension. | ||
==Risk Factors== | ==Risk Factors== | ||
Risk factors of pulmonary hypertension are divided as follows:<ref name="McLaughlin-2009">{{Cite journal | last1 = McLaughlin | first1 = VV. | last2 = Archer | first2 = SL. | last3 = Badesch | first3 = DB. | last4 = Barst | first4 = RJ. | last5 = Farber | first5 = HW. | last6 = Lindner | first6 = JR. | last7 = Mathier | first7 = MA. | last8 = McGoon | first8 = MD. | last9 = Park | first9 = MH. | title = ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. | journal = Circulation | volume = 119 | issue = 16 | pages = 2250-94 | month = Apr | year = 2009 | doi = 10.1161/CIRCULATIONAHA.109.192230 | PMID = 19332472 }}</ref> | |||
===Pulmonary Arterial Hypertension=== | ===Pulmonary Arterial Hypertension=== | ||
* [[BMPR2]] gene mutation | * [[BMPR2]] gene mutation | ||
| Line 24: | Line 26: | ||
| style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Definite risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Possible risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Likely risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Unlikely risk | | style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Definite risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Possible risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Likely risk || style="padding: 0 5px; font-size: 100%; background: #4682B4; color: #FFFFFF; width: 25%" align="center" |Unlikely risk | ||
|- | |- | ||
| style="font-size: 100; padding: 0 5px; background: # | | style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" | | ||
* [[Aminorex]] | * [[Aminorex]] | ||
* [[Fenfluramine]] | * [[Fenfluramine]] | ||
| Line 30: | Line 32: | ||
* Toxic rapeseed oil | * Toxic rapeseed oil | ||
* [[Benfluorex]] | * [[Benfluorex]] | ||
| style="font-size: 100; padding: 0 5px; background: # | | style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" | | ||
* [[Cocaine]] | * [[Cocaine]] | ||
* [[Phenylpropanolamine]] | * [[Phenylpropanolamine]] | ||
| Line 37: | Line 39: | ||
* [[Selective serotonin reuptake inhibitor]]s | * [[Selective serotonin reuptake inhibitor]]s | ||
* [[Pergolide]] | * [[Pergolide]] | ||
| style="font-size: 100; padding: 0 5px; background: # | | style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" | | ||
* [[Amphetamine]] | * [[Amphetamine]] | ||
* [[L-tryptophan]] | * [[L-tryptophan]] | ||
* [[Metamphetamine]] | * [[Metamphetamine]] | ||
| style="font-size: 100; padding: 0 5px; background: # | | style="font-size: 100; padding: 0 5px; background: #F5F5F5" align="left" | | ||
* [[Oral contraceptive]] | * [[Oral contraceptive]] | ||
* [[Estrogen|Estrogen therapy]] | * [[Estrogen|Estrogen therapy]] | ||
Revision as of 18:15, 26 March 2018
|
Pulmonary Hypertension Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pulmonary hypertension risk factors On the Web |
|
American Roentgen Ray Society Images of Pulmonary hypertension risk factors |
|
Risk calculators and risk factors for Pulmonary hypertension risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Assistant Editor(s)-in-Chief: Ralph Matar; Rim Halaby, M.D. [2]
Overview
Pulmonary hypertension (PH) is a multifactorial disease involving genetic and environmental risk factors. Risk factors for pulmonary arterial hypertension include BMPR2 mutation, connective tissue disease, HIV infection, portal hypertension, fenfluramine use, and congenital heart disease with shunt. Left heart and lung diseases are risk factors for PH. Patients with a hypercoagulable state (such as the presence of lupus anticoagulant, deficiency of protein C, protein S, or antithrombin III, chronic inflammatory disorders, myeloproliferative syndromes, and splenectomy) are at an increased risk for chronic thromboembolic pulmonary hypertension.
Risk Factors
Risk factors of pulmonary hypertension are divided as follows:[1]
Pulmonary Arterial Hypertension
- BMPR2 gene mutation
- ALK1 gene mutation
- Connective tissue disease
- HIV infection
- Portal hypertension
- Congenital heart disease
- Schistosomiasis
- Chronic hemolytic anemia
- Drugs and toxins
Shown below is a table summarizing the list of drugs associated with PAH.
| Definite risk | Possible risk | Likely risk | Unlikely risk |
|
Pulmonary hypertension due to Left Heart Disease
Pulmonary Hypertension due to Lung Diseases and/or Hypoxia
- Alveolar hypoventilation disorders
- Chronic exposure to high altitude
- Chronic obstructive pulmonary disease
- Developmental abnormalities
- Interstitial lung disease
- Pulmonary diseases with mixed restrictive and obstructive pattern
- Sleep related breathing problems
Chronic Thromboembolic Pulmonary Hypertension
- Pulmonary embolism
- Hypercoagulability (lupus anticoagulant, deficiency of protein C, protein S, or antithrombin III, chronic inflammatory disorders, myeloproliferative syndromes, and splenectomy)
PH with Unclear and/or Multifactorial Mechanisms
- Myeloproliferative disease
- Splenectomy
- Sarcoidosis
- Histiocytosis
- Lymphangioleiomyomatosis
- Neurofibromatosis
- Vasculitis
- Glycogen storage disease
- Gaucher disease
- Thyroid disorder
- Obstruction by tumor
- Fibrosing mediastinitis
- Chronic renal failure on dialysis
References
- ↑ McLaughlin, VV.; Archer, SL.; Badesch, DB.; Barst, RJ.; Farber, HW.; Lindner, JR.; Mathier, MA.; McGoon, MD.; Park, MH. (2009). "ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association". Circulation. 119 (16): 2250–94. doi:10.1161/CIRCULATIONAHA.109.192230. PMID 19332472. Unknown parameter
|month=ignored (help)